Showing 1051-1060 of 20386 results for "".
Next-Generation Innovations: The Future of CELMoDs in Myeloma
https://reachmd.com/programs/cme/next-generation-innovations-the-future-of-celmods-in-myeloma/36575/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma ActivityOngoing Clinical Trials in AML With Menin Inhibitors
https://reachmd.com/programs/cme/ongoing-clinical-trials-in-aml-with-menin-inhibitors/36185/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.Clinical Evidence on Monotherapy With Menin Inhibitors in R/R AML
https://reachmd.com/programs/cme/clinical-evidence-on-monotherapy-with-menin-inhibitors-in-rr-aml/36180/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
https://reachmd.com/programs/acc-action-center/no-improvements-in-cv-outcomes-at-90-days-with-human-apoa-1-infusions-post-mi/24288/ACC.24 - Michael Gibson shares the results of the AEGIS-II trial, in which infusions of human ApoA-1 - the building block of HDL-c - with CSL112 in the first month after an MI did not improve CV mortality, MI or stroke at 90 days.The Critical Interplay: CKD, HF, and HyperkaleAmia
https://reachmd.com/programs/cme/the-critical-interplay-ckd-hf-and-hyperkalemia/36193/Learn from a multidisciplinary faculty panel how to Improve outcomes for patients with CKD and HFrEF using optimal RAASi and MRAs while managing hyperkalemia with potassium binders.Integrating Guideline Updates in Squamous Cell Carcinoma of the Anal Canal
https://reachmd.com/programs/project-oncology/guideline-updates-anal-canal-squamous-cell-carcinoma/54280/As NCCN® Clinical Practice Guidelines in Oncology evolve, integrating chemoimmunotherapy into the management of advanced squamous cell carcinoma of the anal canal requires thoughtful, patient-centered decision-making. That’s why Dr. Stacey Cohen joins Dr. Charles Turck to translate updated recommendHypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
https://reachmd.com/clinical-practice/cardiology/hypertrophic-cardiomyopathy-moving-from-monitoring-to-action-in-the-era-of-myosin-inhibitors/56461/Find out how myosin inhibitor data support timely identification and treatment of eligible patients with HCM.Decoding Itch in CKD: From CKD-aP Suspicion to Solution
https://reachmd.com/programs/cme/decoding-itch-in-ckd-from-ckd-ap-suspicion-to-solution/26640/Review best practices in CKD-aP diagnosis, treatment and management, including the role of multidisciplinary care and shared decision-making to improve quality of life.Practical Dermatology Roundtable: The Role of Adjuvant Skin Cleansing and Moisturizing in Treating Psoriasis and Other Inflammatory Diseases, Ch. 7
https://reachmd.com/programs/the-practical-dermatology-roundtable/practical-dermatology-roundtable-the-role-of-adjuvant-skin-cleansing-and-moisturizing-in-treating-psoriasis-and-other-inflammatory-diseases-ch-7/56875/In the seventh installment of this eight-part series, host Ted Lain, MD, MBA, FAAD, and guests Zoe Diana Draelos, MD, and Firas George Hougeir, MD, FAAD, shift to clinical applications, including maintenance therapy, steroid-sparing strategies, and opportunities for future research.1 Draelos Z, HouFrom Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
https://reachmd.com/programs/cme/from-evidence-to-action-integrating-emerging-myosin-inhibitors-into-ohcm-treatment-plans/54841/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.